AST
Selected indexed studies
- Elevated ALT/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States. (Front Endocrinol (Lausanne), 2024) [PMID:39253584]
- AST-120 for the management of progression of chronic kidney disease. (Int J Nephrol Renovasc Dis, 2014) [PMID:24501542]
- Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy? (Nephron, 2017) [PMID:27960172]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Elevated ALT/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States. (2024) pubmed
- AST-120 for the management of progression of chronic kidney disease. (2014) pubmed
- Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy? (2017) pubmed
- Pharmacological Actions of Indoxyl Sulfate and AST-120 That Should Be Recognized for the Strategic Treatment of Patients with Chronic Kidney Disease. (2020) pubmed
- Neuroprotective effect of astragalin via activating PI3K/Akt-mTOR-mediated autophagy on APP/PS1 mice. (2023) pubmed
- High AST/ALT Ratio Is Associated with Cardiac Involvement in Acute COVID-19 Patients. (2023) pubmed
- Review of the efficacy of AST-120 (KREMEZIN(®)) on renal function in chronic kidney disease patients. (2019) pubmed
- AST and ALT APRI Scores and Dysglycemia in Saudi Arabia: A Retrospective Population Study. (2023) pubmed
- The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective. (2015) pubmed
- AST-120 improved uremic pruritus by lowering indoxyl sulfate and inflammatory cytokines in hemodialysis patients. (2024) pubmed